Company Filing History:
Years Active: 2011-2012
Title: Inventor Spotlight: Patrick Albientz
Introduction
Patrick Albientz is an innovative inventor based in St. Louis Neuweg, France. He has made significant contributions to the field of pharmaceuticals, particularly in drug monitoring assays. With a total of two patents to his name, Albientz continues to demonstrate his expertise in developing advanced methods for pharmaceutical applications.
Latest Patents
Albientz's latest patents revolve around a novel drug monitoring assay. This method focuses on obtaining binding agents that have a higher specificity for pharmaceutically active forms of compounds compared to their inactive forms. The invention includes the use of special derivatives of the parent compound, enhancing the efficacy of the binding agents. His work in this area also encompasses the creation of drug monitoring assays utilizing these binding agents for better monitoring of the active forms of the parent compound.
Career Highlights
Currently, Patrick Albientz works with Novartis AG, a leading global healthcare company. His position allows him to leverage his patent innovations to significantly impact patient care through improved drug monitoring techniques. His focus on precision in pharmaceuticals underscores his dedication to advancing medical science.
Collaborations
Throughout his career, Albientz has collaborated with notable colleagues, including Jean-Michel Grenet and Rainer Hillenbrand. These partnerships highlight a strong teamwork ethos within Novartis AG, fostering an environment where innovative ideas can flourish and lead to successful developments in the field.
Conclusion
Patrick Albientz stands out as a significant contributor to pharmaceutical innovation through his patented inventions. His focus on specialized binding agents for drug monitoring not only exemplifies his expertise but also showcases the collaborative efforts within the industry. As he continues to develop groundbreaking methods, the impact of his work at Novartis AG is poised to benefit the medical community and improve patient outcomes.